Biolinerx Ltd ADR (BLRX)

$3.28 -0.11 (-3.24%)
Market Cap 14.81M
Revenue (ttm) 1.18M
Net Income (ttm) -1.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -100.00%
Debt to Equity Ratio 0.38
Volume 19,900
Avg Vol 58,336
Day's Range N/A - N/A
Shares Out 4.37M
Stochastic %K 88%
Beta 1.53
Analysts Strong Sell
Price Target $20.33

Company Profile

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multip...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 8 642 9100
Fax: 972 8 642 9101
Address:
Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, Israel
MegansKEY
MegansKEY Jun. 4 at 10:27 AM
$TDTH $BLRX $ICU $GNLN sport
0 · Reply
tankwfwf
tankwfwf May. 31 at 10:57 PM
$BLRX NBC had a segment on the new experimental drug DARAXONRASIB and its success. I don't think Phil can keep blowing smoke up investors asses about alhexa so he can keep a job. Check it out. Remember Phil is a liar and a thief.
0 · Reply
ZacksSCR
ZacksSCR May. 28 at 7:19 PM
$BLRX: First Quarter 2026 Results https://buff.ly/v9eQPhK
0 · Reply
TwongStocks
TwongStocks May. 27 at 2:01 PM
$BLRX In light of RVMD's PDAC data, I wouldn't be surprised if they eventually end up stopping PDAC development for motixafortide unless they can show enough efficacy to compete. If they do, then there focus would be completely on GLIX1, unless they license additional assets. ---------------------- "As far as next steps, I think that we can’t ignore the fact that there was new data from Revolution Medicines that has come out that may have a significant effect on the PDAC landscape at this point. Obviously that’s good news for the patients, but we are looking at what signal we would like to see and what would support CXCR4 inhibition as sort of a backbone agnostic adjunctive strategy across platforms because we expect probably the treatment platform or the treatment paradigm will be changing in the next couple of years. I think that we have to look at the data that we see and then make some decisions later on about how best to proceed."
2 · Reply
EarningsInsider
EarningsInsider May. 27 at 1:38 PM
https://www.marketbeat.com/earnings/reports/2026-5-27-biolinerx-ltd-stock/ $BLRX BioLineRx Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 27 at 11:42 AM
$BLRX Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.00 • Reported revenue of $0.48M up 87.06% YoY • BioLineRx is maintaining its cash runway guidance into the first half of 2027 with $17.4M on its balance sheet as of March 31, 2026.
0 · Reply
DARKP00L
DARKP00L May. 27 at 11:10 AM
$BLRX 07:03 on May. 27 2026 BioLine Rx Q1 Sales $477.000K Beat $343.000K Estimate #tradeideas
0 · Reply
TwongStocks
TwongStocks May. 27 at 11:06 AM
$BLRX Q1 earnings release https://www.prnewswire.com/news-releases/biolinerx-reports-first-quarter-2026-financial-results-and-provides-corporate-update-302782918.html • BLRX received $477K in royalty revenue from Ayrmid ($2.7m in Aphexda sales). • $17.4m in cash as of Mar 31, runway into 1H 2027. • No milestone payments reported from Ayrmid or Gloria. It appears last year's Aphexda sales were not high enough to trigger a milestone payment from Ayrmid.
0 · Reply
Paulfrench
Paulfrench May. 25 at 9:19 AM
$BLRX Graphically we have a very nice bullish reversal setup here...
1 · Reply
robsmi63
robsmi63 May. 22 at 8:42 PM
$BLRX
0 · Reply
Latest News on BLRX
BioLineRx (BLRX) Q1 2026 Earnings Transcript

2026-05-29T18:16:10.000Z - 5 days ago

BioLineRx (BLRX) Q1 2026 Earnings Transcript

BLRX Achieves Key Milestones in Clinical Development and Revenue Growth

2026-05-27T12:55:07.000Z - 7 days ago

BLRX Achieves Key Milestones in Clinical Development and Revenue Growth

BioLineRx Earnings Call Transcript: Q1 2026

May 27, 2026, 8:30 AM EDT - 7 days ago

BioLineRx Earnings Call Transcript: Q1 2026

BioLineRx Earnings release: Q1 2026

May 27, 2026, 8:30 AM EDT - 7 days ago

BioLineRx Earnings release: Q1 2026

BioLineRx reports Q1 EPS 0c vs. (0c) last year

2026-05-27T11:28:44.000Z - 7 days ago

BioLineRx reports Q1 EPS 0c vs. (0c) last year

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 27 May 2026 07:00:00 -0400 - 8 days ago

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

BioLineRx to Present GLIX1 Preclinical Data at ASCO 2026

2026-05-22T17:10:56.000Z - 12 days ago

BioLineRx to Present GLIX1 Preclinical Data at ASCO 2026

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

Fri, 22 May 2026 07:00:00 -0400 - 13 days ago

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

BioLineRx to Report First Quarter 2026 Results on May 27, 2026

Wed, 20 May 2026 07:00:00 -0400 - 15 days ago

BioLineRx to Report First Quarter 2026 Results on May 27, 2026

BioLineRx (BLRX) Reports Promising Preclinical Results for GLIX1 in GBM Treatment

2026-05-19T12:28:42.000Z - 15 days ago

BioLineRx (BLRX) Reports Promising Preclinical Results for GLIX1 in GBM Treatment

BioLineRx and Hemispherian report new GLIX1 anti-tumor effect in GBM

2026-05-19T11:13:18.000Z - 15 days ago

BioLineRx and Hemispherian report new GLIX1 anti-tumor effect in GBM

BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts

Tue, 19 May 2026 07:00:00 -0400 - 16 days ago

BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts

BioLineRx (BLRX) Begins Phase 1/2a Study of GLIX1 for Glioblastoma Treatment

2026-04-28T13:30:37.000Z - 5 weeks ago

BioLineRx (BLRX) Begins Phase 1/2a Study of GLIX1 for Glioblastoma Treatment

BioLineRx, Hemispherian: First patient dosed in Phase 1/2a Study of GLIX1

2026-04-28T11:46:36.000Z - 5 weeks ago

BioLineRx, Hemispherian: First patient dosed in Phase 1/2a Study of GLIX1

BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

Tue, 28 Apr 2026 07:00:00 -0400 - 5 weeks ago

BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

BioLineRx (BLRX) Partners in Groundbreaking Glioblastoma Trial

2026-04-08T10:50:48.000Z - 2 months ago

BioLineRx (BLRX) Partners in Groundbreaking Glioblastoma Trial

BioLineRx, Hemispherian initiate clinical trial of GLIX1

2026-04-08T09:26:21.000Z - 2 months ago

BioLineRx, Hemispherian initiate clinical trial of GLIX1

Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma

Wed, 08 Apr 2026 02:30:00 -0400 - 2 months ago

Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma

BioLineRx initiates Phase 1/2a study of GLIX1

2026-03-26T11:08:04.000Z - 2 months ago

BioLineRx initiates Phase 1/2a study of GLIX1

BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

Thu, 26 Mar 2026 07:00:00 -0400 - 2 months ago

BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

BioLineRx Earnings Call Transcript: Q4 2025

Mar 23, 2026, 8:30 AM EDT - 2 months ago

BioLineRx Earnings Call Transcript: Q4 2025

BioLineRx Annual report: Q4 2025

Mar 23, 2026, 8:30 AM EDT - 2 months ago

BioLineRx Annual report: Q4 2025

BioLineRx Earnings release: Q4 2025

Mar 23, 2026, 8:30 AM EDT - 2 months ago

BioLineRx Earnings release: Q4 2025

Options Volatility and Implied Earnings Moves Today, March 23, 2026

2026-03-23T12:06:18.000Z - 2 months ago

Options Volatility and Implied Earnings Moves Today, March 23, 2026

LAR MBX

Earnings Scheduled For March 23, 2026

2026-03-23T11:11:27.000Z - 2 months ago

Earnings Scheduled For March 23, 2026

BioLineRx provides corporate update

2026-03-23T11:10:51.000Z - 2 months ago

BioLineRx provides corporate update

BioLineRx Reports 2025 Financial Results and Provides Corporate Update

Mon, 23 Mar 2026 07:00:00 -0400 - 2 months ago

BioLineRx Reports 2025 Financial Results and Provides Corporate Update

BioLineRx (BLRX) and Others Set to Announce Earnings

2026-03-23T00:55:17.000Z - 2 months ago

BioLineRx (BLRX) and Others Set to Announce Earnings

BioLineRx to Report 2025 Annual Results on March 23, 2026

Mon, 16 Mar 2026 07:00:00 -0400 - 2 months ago

BioLineRx to Report 2025 Annual Results on March 23, 2026

BioLineRx Earnings Call Transcript: Q3 2025

Nov 24, 2025, 8:30 AM EST - 6 months ago

BioLineRx Earnings Call Transcript: Q3 2025

BioLineRx Earnings release: Q3 2025

Nov 24, 2025, 8:30 AM EST - 6 months ago

BioLineRx Earnings release: Q3 2025

BioLineRx (BLRX) Surpasses Q3 EPS Estimates Despite Revenue Shortfall

2025-11-24T13:01:39.000Z - 6 months ago

BioLineRx (BLRX) Surpasses Q3 EPS Estimates Despite Revenue Shortfall

BioLineRx (BLRX) Q3 Revenue Declines Amid New Joint Venture

2025-11-24T12:34:08.000Z - 6 months ago

BioLineRx (BLRX) Q3 Revenue Declines Amid New Joint Venture

Options Volatility and Implied Earnings Moves Today, November 24, 2025

2025-11-24T12:05:22.000Z - 6 months ago

Options Volatility and Implied Earnings Moves Today, November 24, 2025

A BLBD FLNC KEYS LX PFLT SMTC

BioLineRx reports Q3 EPS 0c vs 0c last year

2025-11-24T12:05:10.000Z - 6 months ago

BioLineRx reports Q3 EPS 0c vs 0c last year

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Mon, 24 Nov 2025 07:00:00 -0500 - 6 months ago

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Earnings Scheduled For November 24, 2025

2025-11-24T11:11:10.000Z - 6 months ago

Earnings Scheduled For November 24, 2025

BioLine Rx's Earnings: A Preview

2025-11-21T15:01:37.000Z - 6 months ago

BioLine Rx's Earnings: A Preview

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Tue, 18 Nov 2025 07:00:00 -0500 - 7 months ago

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

BioLineRx Slides: Corporate Presentation

Nov 18, 2025, 7:00 AM EST - 7 months ago

BioLineRx Slides: Corporate Presentation

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

Mon, 17 Nov 2025 07:00:00 -0500 - 7 months ago

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

BioLineRx (BLRX) and Hemispherian Collaborate on Innovative Cancer Therapy

2025-09-29T12:33:46.000Z - 8 months ago

BioLineRx (BLRX) and Hemispherian Collaborate on Innovative Cancer Therapy

BioLineRx Transcript: Study Update

Sep 29, 2025, 8:30 AM EDT - 8 months ago

BioLineRx Transcript: Study Update

BioLineRx Press release: Study Update

Sep 29, 2025, 8:30 AM EDT - 8 months ago

BioLineRx Press release: Study Update

BioLineRx Slides: Study Update

Sep 29, 2025, 8:30 AM EDT - 8 months ago

BioLineRx Slides: Study Update

BioLineRx, Hemispherian AS establish joint venture to develop GLIX1

2025-09-29T11:10:48.000Z - 8 months ago

BioLineRx, Hemispherian AS establish joint venture to develop GLIX1

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

Mon, 29 Sep 2025 07:00:00 -0400 - 8 months ago

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

BioLineRx Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 10 months ago

BioLineRx Earnings Call Transcript: Q2 2025

BioLineRx Earnings release: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 10 months ago

BioLineRx Earnings release: Q2 2025

BioLineRx reports Q2 EPS 0c vs. 0c last year

2025-08-14T11:05:57.000Z - 10 months ago

BioLineRx reports Q2 EPS 0c vs. 0c last year

Options Volatility and Implied Earnings Moves Today, August 14, 2025

2025-08-14T11:05:16.000Z - 10 months ago

Options Volatility and Implied Earnings Moves Today, August 14, 2025

AMAT BTBT CSCO DE JD KULR NTES

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 7:00 AM EDT - 10 months ago

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

Aug 7, 2025, 7:00 AM EDT - 10 months ago

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

3 Stocks Getting Rare Double Upgrades From Analysts

Jun 6, 2025, 2:30 PM EDT - 1 year ago

3 Stocks Getting Rare Double Upgrades From Analysts

AAP BUD

BioLineRx upgraded to Buy from Hold at JonesResearch

2025-05-30T12:46:29.000Z - 1 year ago

BioLineRx upgraded to Buy from Hold at JonesResearch

BioLineRx announces new data from Phase 2 combination trial of motixafortide

2025-05-30T11:05:10.000Z - 1 year ago

BioLineRx announces new data from Phase 2 combination trial of motixafortide

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

May 30, 2025, 7:00 AM EDT - 1 year ago

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

BioLineRx Earnings Call Transcript: Q1 2025

May 27, 2025, 8:30 AM EDT - 1 year ago

BioLineRx Earnings Call Transcript: Q1 2025

BioLineRx Earnings release: Q1 2025

May 27, 2025, 8:30 AM EDT - 1 year ago

BioLineRx Earnings release: Q1 2025

BioLineRx reports Q1 EPS 0c vs. 0c last year

2025-05-27T11:05:36.000Z - 1 year ago

BioLineRx reports Q1 EPS 0c vs. 0c last year

Options Volatility and Implied Earnings Moves Today, May 27, 2025

2025-05-27T11:05:32.000Z - 1 year ago

Options Volatility and Implied Earnings Moves Today, May 27, 2025

AZO BNS BOX GLNG OKTA PDD SHIP

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 27, 2025, 7:00 AM EDT - 1 year ago

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

May 20, 2025, 7:00 AM EDT - 1 year ago

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

BioLineRx downgraded to Hold from Buy at JonesResearch

2025-04-01T20:36:11.000Z - 1 year ago

BioLineRx downgraded to Hold from Buy at JonesResearch

BLRX

BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split

2025-03-31T15:20:07.000Z - 1 year ago

BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split

BLRX

BioLineRx Earnings Call Transcript: Q4 2024

Mar 31, 2025, 8:30 AM EDT - 1 year ago

BioLineRx Earnings Call Transcript: Q4 2024

BioLineRx Annual report: Q4 2024

Mar 31, 2025, 8:30 AM EDT - 1 year ago

BioLineRx Annual report: Q4 2024

BioLineRx Earnings release: Q4 2024

Mar 31, 2025, 8:30 AM EDT - 1 year ago

BioLineRx Earnings release: Q4 2024

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 7:00 AM EDT - 1 year ago

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

BioLineRx to Report 2024 Annual Results on March 31, 2025

Mar 24, 2025, 7:00 AM EDT - 1 year ago

BioLineRx to Report 2024 Annual Results on March 31, 2025

BioLineRx Issues Letter to Shareholders

Jan 21, 2025, 7:00 AM EST - 1 year ago

BioLineRx Issues Letter to Shareholders

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

Jan 17, 2025, 7:00 AM EST - 1 year ago

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

BioLineRx Announces $10 Million Registered Direct Offering

Jan 6, 2025, 8:57 AM EST - 1 year ago

BioLineRx Announces $10 Million Registered Direct Offering

BioLineRx Earnings Call Transcript: Q3 2024

Nov 25, 2024, 8:30 AM EST - 1 year ago

BioLineRx Earnings Call Transcript: Q3 2024

BioLineRx Earnings release: Q3 2024

Nov 25, 2024, 8:30 AM EST - 1 year ago

BioLineRx Earnings release: Q3 2024

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

Nov 25, 2024, 7:00 AM EST - 1 year ago

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Nov 21, 2024, 6:30 AM EST - 1 year ago

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

Nov 20, 2024, 7:19 AM EST - 1 year ago

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

Oct 16, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

Sep 17, 2024, 1:01 PM EDT - 1 year ago

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

BioLineRx Earnings Call Transcript: Q2 2024

Aug 15, 2024, 8:30 AM EDT - 1 year ago

BioLineRx Earnings Call Transcript: Q2 2024

BioLineRx Earnings release: Q2 2024

Aug 15, 2024, 8:30 AM EDT - 1 year ago

BioLineRx Earnings release: Q2 2024

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

Aug 15, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

May 30, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

BioLineRx Earnings Call Transcript: Q1 2024

May 28, 2024, 8:30 AM EDT - 2 years ago

BioLineRx Earnings Call Transcript: Q1 2024

BioLineRx Earnings release: Q1 2024

May 28, 2024, 8:30 AM EDT - 2 years ago

BioLineRx Earnings release: Q1 2024

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

May 28, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

May 24, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

May 22, 2024, 7:00 AM EDT - 2 years ago

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

May 17, 2024, 5:00 PM EDT - 2 years ago

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

May 6, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

Apr 17, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

Apr 10, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

BioLineRx Announces $6 Million Registered Direct Offering

Apr 1, 2024, 9:00 AM EDT - 2 years ago

BioLineRx Announces $6 Million Registered Direct Offering

BioLineRx Earnings Call Transcript: Q4 2023

Mar 26, 2024, 8:30 AM EDT - 2 years ago

BioLineRx Earnings Call Transcript: Q4 2023

BioLineRx Annual report: Q4 2023

Mar 26, 2024, 8:30 AM EDT - 2 years ago

BioLineRx Annual report: Q4 2023

BioLineRx Earnings release: Q4 2023

Mar 26, 2024, 8:30 AM EDT - 2 years ago

BioLineRx Earnings release: Q4 2023

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

Mar 26, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Mar 20, 2024, 7:00 AM EDT - 2 years ago

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Mar 6, 2024, 8:00 AM EST - 2 years ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

CADL IMRX ONCY

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

Mar 4, 2024, 7:00 AM EST - 2 years ago

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

Feb 28, 2024, 7:00 AM EST - 2 years ago

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Feb 16, 2024, 7:00 AM EST - 2 years ago

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

BioLineRx Registration statement: Registration Filing

Dec 29, 2023, 7:00 AM EST - 2 years ago

BioLineRx Registration statement: Registration Filing

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

Dec 21, 2023, 7:00 AM EST - 2 years ago

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

BioLineRx Earnings Call Transcript: Q3 2023

Nov 20, 2023, 10:00 AM EST - 2 years ago

BioLineRx Earnings Call Transcript: Q3 2023

BioLineRx Earnings release: Q3 2023

Nov 20, 2023, 10:00 AM EST - 2 years ago

BioLineRx Earnings release: Q3 2023

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

Nov 20, 2023, 7:00 AM EST - 2 years ago

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures

Oct 31, 2023, 9:00 AM EDT - 2 years ago

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures

MegansKEY
MegansKEY Jun. 4 at 10:27 AM
$TDTH $BLRX $ICU $GNLN sport
0 · Reply
tankwfwf
tankwfwf May. 31 at 10:57 PM
$BLRX NBC had a segment on the new experimental drug DARAXONRASIB and its success. I don't think Phil can keep blowing smoke up investors asses about alhexa so he can keep a job. Check it out. Remember Phil is a liar and a thief.
0 · Reply
ZacksSCR
ZacksSCR May. 28 at 7:19 PM
$BLRX: First Quarter 2026 Results https://buff.ly/v9eQPhK
0 · Reply
TwongStocks
TwongStocks May. 27 at 2:01 PM
$BLRX In light of RVMD's PDAC data, I wouldn't be surprised if they eventually end up stopping PDAC development for motixafortide unless they can show enough efficacy to compete. If they do, then there focus would be completely on GLIX1, unless they license additional assets. ---------------------- "As far as next steps, I think that we can’t ignore the fact that there was new data from Revolution Medicines that has come out that may have a significant effect on the PDAC landscape at this point. Obviously that’s good news for the patients, but we are looking at what signal we would like to see and what would support CXCR4 inhibition as sort of a backbone agnostic adjunctive strategy across platforms because we expect probably the treatment platform or the treatment paradigm will be changing in the next couple of years. I think that we have to look at the data that we see and then make some decisions later on about how best to proceed."
2 · Reply
EarningsInsider
EarningsInsider May. 27 at 1:38 PM
https://www.marketbeat.com/earnings/reports/2026-5-27-biolinerx-ltd-stock/ $BLRX BioLineRx Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 27 at 11:42 AM
$BLRX Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.00 • Reported revenue of $0.48M up 87.06% YoY • BioLineRx is maintaining its cash runway guidance into the first half of 2027 with $17.4M on its balance sheet as of March 31, 2026.
0 · Reply
DARKP00L
DARKP00L May. 27 at 11:10 AM
$BLRX 07:03 on May. 27 2026 BioLine Rx Q1 Sales $477.000K Beat $343.000K Estimate #tradeideas
0 · Reply
TwongStocks
TwongStocks May. 27 at 11:06 AM
$BLRX Q1 earnings release https://www.prnewswire.com/news-releases/biolinerx-reports-first-quarter-2026-financial-results-and-provides-corporate-update-302782918.html • BLRX received $477K in royalty revenue from Ayrmid ($2.7m in Aphexda sales). • $17.4m in cash as of Mar 31, runway into 1H 2027. • No milestone payments reported from Ayrmid or Gloria. It appears last year's Aphexda sales were not high enough to trigger a milestone payment from Ayrmid.
0 · Reply
Paulfrench
Paulfrench May. 25 at 9:19 AM
$BLRX Graphically we have a very nice bullish reversal setup here...
1 · Reply
robsmi63
robsmi63 May. 22 at 8:42 PM
$BLRX
0 · Reply
tankwfwf
tankwfwf May. 22 at 3:12 PM
$BLRX 💩💩💩💩💩💩💩💩
0 · Reply
DARKP00L
DARKP00L May. 22 at 11:35 AM
$BLRX 07:06 on May. 22 2026 BioLineRx And Hemispherian Announce Two Abstracts Featuring GLIX1 Will Be Published At ASCO 2026 Annual Meeting #tradeideas
0 · Reply
SuperGreenToday
SuperGreenToday May. 22 at 4:34 AM
$BLRX Share Price: $2.81 Contract Selected: Nov 20, 2026 $5 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.65 – $0.80 Potential Upside: 61% ROI Time to Expiration: 182 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
TwongStocks
TwongStocks May. 20 at 5:01 PM
$BLRX It's been a while for them, but it looks like they may have tapped into the ATM again. TASE is showing an increase in outstanding shares. https://market.tase.co.il/en/market_data/security/1101518/historical_data/eod 1 ADS on NASDAQ = 600 ordinary shares on TASE. This is the first share increase reported since Sept 2025. Which also happened to be the last qtr they reported using the ATM.
0 · Reply
DiaJay
DiaJay May. 19 at 3:43 PM
$BLRX A nothing burger again. I am not impressed. BLRX continues to be a failing company. Stay away retail. This company is 99.5% failure and .05 Hopism from conmen.
0 · Reply
OpenOutcrier
OpenOutcrier May. 19 at 12:32 PM
$BLRX (-2.5% pre) BioLineRx reports positive preclinical data for GLIX1 in brain cancer https://ooc.bz/l/102810
0 · Reply
DARKP00L
DARKP00L May. 19 at 11:56 AM
$BLRX 07:04 on May. 19 2026 BioLineRx Announces New Preclinical Data That Further Support The Recently Initiated Phase 1/2a Clinical Trial Evaluating GLIX1 For Recurrent And Progressive GBM And Other High-Grade Gliomas #tradeideas
0 · Reply
Trader1141
Trader1141 May. 19 at 11:55 AM
$BLRX datta that bad?…. Lol im out
0 · Reply
Trader1141
Trader1141 May. 19 at 11:21 AM
$BLRX say what now? Lol
0 · Reply
DARKP00L
DARKP00L May. 19 at 11:15 AM
$BLRX 07:04 on May. 19 2026 BioLineRx Announces New Preclinical Data That Further Support The Recently Initiated Phase 1/2a Clinical Trial Evaluating GLIX1 For Recurrent And Progressive GBM And Other High-Grade Gliomas #tradeideas
0 · Reply
Prosperity_Partners
Prosperity_Partners May. 19 at 11:07 AM
$BLRX BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts | Float: 4.3 M | IO: 0.45% | MC: 12.2 M
0 · Reply
TwongStocks
TwongStocks May. 19 at 11:02 AM
$BLRX BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-and-hemispherian-announce-new-glix1-data-demonstrating Preclinical data. BioLineRx and Hemispherian plan to present the data from these studies at one or more future medical conferences.
0 · Reply